morpholinoanthracycline mx2 has been researched along with tetradecanoylphorbol acetate in 1 studies
| Studies (morpholinoanthracycline mx2) | Trials (morpholinoanthracycline mx2) | Recent Studies (post-2010) (morpholinoanthracycline mx2) | Studies (tetradecanoylphorbol acetate) | Trials (tetradecanoylphorbol acetate) | Recent Studies (post-2010) (tetradecanoylphorbol acetate) |
|---|---|---|---|---|---|
| 53 | 15 | 0 | 31,050 | 61 | 2,217 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujiwara, Y; Kasahara, K; Kubo, S; Niitani, H; Nishio, K; Saijo, N; Sugimoto, Y; Takeda, Y | 1 |
1 other study(ies) available for morpholinoanthracycline mx2 and tetradecanoylphorbol acetate
| Article | Year |
|---|---|
Establishment of a human leukemia subline resistant to the growth-inhibitory effect of 12-O-tetradecanoylphorbol 13-acetate (TPA) and showing non-P-glycoprotein-mediated multi-drug resistance.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carubicin; Cell Division; Cell Line; Cell Survival; Doxorubicin; Drug Resistance; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Glycoproteins; Subcellular Fractions; Tetradecanoylphorbol Acetate | 1991 |